SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharmaceutical receives CCI nod for acquisition of Ranbaxy Laboratories

09 Dec 2014 Evaluate

Sun Pharmaceutical Industries and Ranbaxy Laboratories have received the order of the Competition Commission of India (CCI) dated December 5, 2014 by which CCI has approved the acquisition of Ranbaxy by Sun Pharma, subject to compliance with certain conditions.

Sun Pharma and Ranbaxy had filed the notice with the CCI on May 06, 2014 and sought its approval with respect to the deal. Over the past few months, the CCI has sought information and detailed clarifications for the purposes of making its assessment. One of the preconditions of the order is that parties procure the divestment of seven products. These products constitute less than 1% of the combined entity’s revenues in India.

The seven formulations include tamsulosin + tolterodine (combined market share of 90-95 percent); rosuvastatin + ezetimibe (90-95 percent); and leuprorelin (85-90 percent). The others which adversely impact the market but their share is less than 80 percent are terlipressin (65-70 percent); olanzapine + fluoxetine (65-70 percent); levosulpiride + esomeprazole (60-65 percent); and olmesartan + amlodipine + hydroclorthiazide (40-45 percent). According to the terms inked between Ranbaxy and Sun Pharmaceuticals in April, each Ranbaxy shareholder will get 0.8 shares of Sun Pharmaceuticals for every share of Ranbaxy.

Sun Pharma Inds. Share Price

1847.30 12.90 (0.70%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×